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Background: The differential diagnosis of benign and malignant effusion is often hampered by low cell content or
insufficiently preserved tumor cells. In this study, we evaluated the combined diagnostic value of six tumor markers
measured by well-based reverse-phase protein array (RPPA) for diagnosis of malignant effusion.
Methods: A total of 114 patients (46 with malignant effusions, 32 with probable malignant effusions, and 36
with benign effusions) were enrolled. Expressional levels of MUC1, EMA, Pan-CK, HSP90, TGF-β and CA125 were
determined by well-based RPPA.
Results: Median relative expression of MUC1, Pan-CK and EMA were significantly higher in malignant effusion than
those in probable malignant or benign (p < 0.001, p = 0.003, p < 0.001, respectively), whereas the level of TGF-β in
malignant effusions were significantly lower than that in the other groups (p = 0.005). For predicting malignancy,
EMA presented the best areas under the curve of 0.728 followed by MUC1 of 0.701. The sensitivity of 52.0% for
MUC1 and 48.0% for EMA were not better than cytology. However, sensitivity, negative predictive value, and
accuracy of the tumor marker panel were better than cytology by 14.7%, 7.5%, and 6.1%, respectively.
Conclusions: Tumor marker panel measured by well-based RPPA showed values in the differential diagnosis
between benign and malignant effusions. Further large scale studies need to be performed to evaluate the utility
of this panel of markers.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1433424467160224
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Effusions are common complications in patients with ad-
vanced or metastatic tumors, but also seen in other dis-
eases, e.g. liver or heart failure or kidney malfunction. It is
important to differentiate between benign and malignant
effusions for rational decision making in choosing the
therapeutic strategy and assessing patients’ prognosis.
Although cytopathological examination is considered a
standard method for the diagnosis of effusions, several* Correspondence: genejock@helix.nih.gov
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unless otherwise stated.challenging issues remain in detecting malignant cells in
the effusion, including low sensitivity [1–3]. Furthermore,
the sensitivity is dependent on the abundance of morpho-
logically intact cells and experience of the cytopathologist.
Especially in pleural effusion, the difficulty lies in separat-
ing normal or reactive mesothelial cells from cells of ma-
lignant mesothelioma or carcinoma. Another limitation is
that current standard cytological examination is often un-
able to distinguish between different types of malignant
cells without the use of special additional studies such
as immunocytochemistry (ICC) or immunohistochemistry
(IHC) on cell blocks [4]. ICC improves the diagnostic ac-
curacy of conventional cytology [5], but there is no agree-
ment on the ideal combination of immune markers used.entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the fluid have been targeted as additional diagnostic dis-
criminators, including β-HCG [6], albumin [7, 8], vascular
permeability factor (VPF) [9], transthyretin [10], CEA
[11], CA19-9 [12], EZH2 [13] and calretinin [14]. In
addition to these single protein approaches, panels com-
bining different markers have also been proposed [15, 16].
These studies show a high interest in being independent
of variable cell content in effusions. Unfortunately, none
of the makers or panels has shown sufficient sensitivity
and specificity to be considered as a potential diagnostic
marker of effusions.
Mucins are proteins of high molecular weight above
100 kDa, and, up to now, 20 different mucins with some
isoforms have been identified. Among them, mucin 1
(MUC1) seems to be the most studied and promising
tumor marker and recently, it was described as a target
for therapy [17]. Epithelial membrane antigen (EMA)
has been applied as an immunocytological marker in
distinction of carcinoma cells versus mesothelioma cells
[18, 19], while the descriptive name implies its primary
lack of detailed characterization of amino acid sequence
or primary coding gene. Confirming this fact, later stud-
ies in 1996 showed that the monoclonal antibody to
EMA binds at the same marker protein as CA15-3 and
MUC1 [20].
Reverse phase protein array (RPPA) is a sensitive and
high throughput technology that uses a sandwich format
for antigen capture. Over the last decade, RPPA has been
applied to a diverse range of sample types including
serum/plasma samples [21, 22]. Here, we used this assay
to assess the expression of MUC1 and other markers
(EMA, Pan-CK, HSP90, TGF-β and CA125) used in im-
munocytochemistry in ascites and pleural fluid. The aim
of this study was to determine the diagnostic values of
combination markers, and with this well-based RPPA
methodology, we expected to demonstrate better distinc-
tion of malignant from benign effusions, independent of
primary tumors and independent of cell content.
Methods
Sample collection
The study subjects consisted of 114 effusion samples, 38
ascites and 76 pleura effusions. Fresh effusion specimens
were collected and centrifuged at × 3000 g for 10 min at
4 °C. The supernatant was stored at −80 °C until the
well-based RPPA was performed. Study samples were
classified into three groups according to the etiology of
the effusion: malignant, probable malignant and benign
effusion. An effusion was categorized as malignant if
malignant cells were found in effusion fluid or in the
biopsy specimen tissue. A diagnosis of probable malig-
nant effusion was made if the effusion fluid cytology was
negative in patients with a known history of a primarymalignancy, after ruling out benign causes of the effu-
sion. The effusion was classified as benign when no ma-
lignant cells were found and no history of a malignant
tumor was known [23]. All effusion samples were col-
lected as pseudonymized samples for proteomic studies,
which was approved by the institutional review board of
the RWTH Aachen University Hospital (approval no. ek
173/06). This study was additionally approved by the
Office of Human Subjects Research at the National
Institutes of Health.
Well-based reverse phase protein array
Protein concentrations of effusion samples were measured
by standard procedures, using the BCA Protein Assay kit
(Pierce Biotechnology, Rockford, IL). Expressional signals
of MUC1, EMA, Pan-CK, HSP90, TGF-β, CA125, and
glyceraldehyde-3-phospahte dehydrogenase (GAPDH) were
determined by well-based RPPA, by means of electrochemi-
luminescence immunoassay [24–26]. The signal of each
marker was normalized for GAPDH signal as in western
blotting. Briefly, five microliters (400 ng/μl) of native sam-
ple were added to Meso Scale Discovery (MSD, Gaithers-
burg, MD) Multi-Spot™ plates (MA2400 96 HB Plate). The
plate was dried at room temperature for 90 min, and the
plate was subsequently incubated at 37 °C for 30 min. The
antigen-coated plates were blocked with 5% nonfat dry milk
in PBST for 60 min at room temperature and further incu-
bated with anti-MUC1 (diluted 1:1000; Mouse monoclo-
nal, clone# MA695, Novocastra, Buffalo Grove, IL),
anti-EMA (diluted 1:1000; Mouse monoclonal, clone#
E29, Dako), anti-Pan-CK (diluted 1:500; Rabbit poly-
clonal, Dako), anti-HSP90 (diluted 1:500; Rabbit poly-
clonal, Cell Signaling), anti-TGF-β (diluted 1:500;
Rabbit polyclonal, Cell Signaling, Denvers, MA), anti-
CA125 (diluted 1:500; Dako, Carpinteria, CA) or anti-
GAPDH (diluted 1:1000; Mouse monoclonal, Calbio-
chem, Gibbstown, NJ) in PBST containing 5% BSA at 4 °
C overnight, followed by 3 washes with PBST. The
plates were incubated for 60 min with goat anti-mouse
or anti-rabbit SULFO-TAG™ antibodies at a dilution of
1:2000 (0.5 μg/ml) with 5% nonfat dry milk in PBST.
The plates were then aspirated and washed three times
with PBST. Finally, MSD-T read buffer was added to the
plates and they were read on the MSD Sector Imager
2400 reader (Meso Scale Discovery). BSA coated wells
were included on each plate as a negative control for
non-specific binding effects. The values from non-
specific wells were subtracted from all standard samples
to calculate actual value. Two independent experiments
were performed with triplicates.
Western blotting
Equal protein amounts (50 μg) of each sample were re-
solved by 4-12% NuPAGE® Novex Bis-Tris polyacrylamide
Braunschweig et al. Diagnostic Pathology  (2015) 10:53 Page 3 of 10gel, and electroblotted to nitrocellulose membrane using
iBlot™ Dry Blotting System (Invitrogen, Carlsbad, CA).
The membranes were blocked with 5% nonfat dry milk
in TBST for 60 min, washed, and subsequently incu-
bated overnight at 4 °C in TBST (50 mM Tris, pH 7.5,
150 mM NaCl, 0.05% Tween-20) with 5% BSA contain-
ing the following antibodies; anti-MUC 1 (diluted
1:1000; Mouse monoclonal, Novocastra), anti-EMA (di-
luted 1:1000; Mouse monoclonal, DAKO) or anti-GAPDH
(diluted 1:5000; Mouse monoclonal, Calbiochem). Specific
bindings were detected with horseradish peroxidase-
labeled anti-mouse antibodies (Chemicon International,
Temecula, CA) and enhanced with SuperSignal Chemilu-
minescence kit (Pierce Biotechnology). Signals were de-
tected on KODAK BIOMAX MR X-ray film (Kodak,
Rochester, NY).
Statistical analysis
The boxplot was used to present the distribution of tumor
markers in effusions. For comparisons between groups,
Chi-square test for categorical variables and the nonpara-
metric Kruskal-Wallis or Mann–Whitney U test for
continuous variables were used. Receiver operating char-
acteristic analysis was used to compare the diagnostic ac-
curacy of different tumor markers. Cut-off values were
selected to maximize the specificity in the diagnosis of ma-
lignant effusion. The combination of tumor markers was
used in a parallel manner with an “or” rule, wherein the test
result was considered positive if the cut-off point for any of

































Fig. 1 Box plots of protein concentration among benign, probable malign
samples origin (a) and disease category (b). The protein concentrations of
Furthermore, the protein concentration of malignant case is higher than be
p < 0.01; ***, p < 0.001was considered significant. All analyses were performed
using SPSS version 21.0 (SPSS Inc., Chicago, IL).
The hierarchical clustering analysis was performed using
R to visualize the tumor marker expression pattern and to
cluster the effusion samples based on the score of seven
antibodies. The pearson uncentered correlation was used
as distance metric with average linkage. Three main clus-
ters of samples were evaluated for an association with
clinicopathological factors using chi-square test.
Results
Etiology and protein concentration of effusion
The specific etiologies of effusions are presented in
Additional file 1: Table S1. Of the 114 cases, 46 (40.4%)
samples (15 ascites and 31 pleural effusions) were malignant
effusions, 32 (28.1%) samples (12 ascites and 20 pleural ef-
fusions) were probable malignant effusions, and 36 (31.6%)
samples (11 ascites and 25 pleural effusions) were benign
effusions. In malignant ascites, ovarian carcinoma was the
most frequent primary (10/15, 66.6%), and in malignant
pleura effusions, non-small cell lung carcinoma was pre-
dominant (19/31, 61.3%). The benign samples were from
patients with heart failure (10/36, 27.8%), liver cirrhosis (16/
36, 44.4%), and inflammatory diseases (10/36, 27.8%).
As expected, the protein concentrations were 1.63-fold
higher in effusion specimens positive for malignancy
by cytological examination compared to those negative
by cytology (mean 81.0 vs 49.8, respectively, p < 0.001).
This pattern was observed in both ascites and pleural



























ant and malignant cases. The protein concentrations are displayed by
cytological positive specimens are higher than negative cases.
nign (p < 0.001) or probable malignant cases (p = 0.032). *, p < 0.05; **,
Table 1 Median titers of tumor markers in study groups
Tumor Markersa Malignant (n = 46) Probable Malignantb (n = 32) Benign (n = 36) P valuec
MUC1 0.355 (0.081-1.830) 0.073 (0.043-0.096) 0.074 (0.046-0.217) < 0.001
EMA 0.131 (0.043-0.810) 0.038 (0.030-0.050) 0.052 (0.038-0.095) < 0.001
Pan-CK 0.059 (0.031-0.188) 0.024 (0.017-0.080) 0.039 (0.025-0.118) 0.003
HSP90 0.206 (0.167-0.258) 0.178 (0.133-0.231) 0.184 (0.148-0.246) 0.172
TGF-β 0.128 (0.113-0.145) 0.171 (0.132-0.220) 0.156 (0.133-0.186) 0.005
CA125 0.149 (0.064-0.269) 0.121 (0.057-0.213) 0.148 (0.070-0.242) 0.258
Data are presented as median (quartiles)
aAfter normalization with GAPDH level, relative expressional signals were represented as a ratio (tumor marker/GAPDH)
bNo malignant effusion but history of malignancy
cSignificance level of Kruskal-Wallis test
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By diagnosis criteria, the protein concentration in malig-
nant effusion and probable malignant effusion were higher
than that in benign effusion (mean 98.3 vs 46.4, p < 0.001
and 77.7 vs. 46.4, p = 0.015, respectively) (Fig. 1b).
Tumor marker assessment by well-based RPPA
To assess the level of the six tumor markers (MUC1,
EMA, Pan-CK, HSP90, TGF-β and CA125), we performed
the well-based RPPA with all ascites and pleural effusions.Fig. 2 Assessments of MUC1, EMA, TGF-β, and Pan-CK expressions by well-
expressions of MUC1 (a), EMA (b), TGF-β (c) and Pan-CK (d) were categoriz
of each protein to GAPDH. MUC1 and EMA expressions of malignant cases
respectively). (e) MUC1 and EMA protein levels were analysed by western b
graph shows the average ± SD of two independent experiments. M, malign
positive cytology; *, p < 0.05; **, p < 0.01; ***, p < 0.001Results of tumor markers quantitation by the well-based
RPPA are summarized in Table 1. Median relative expres-
sions of MUC1, Pan-CK and EMA were significantly
higher in malignant effusion than those in probable malig-
nant or benign (p < 0.001, p = 0.003, p < 0.001, respect-
ively), whereas the level of TGF-β were significantly lower
in malignant effusions than that in the other groups
(p = 0.005) (Table 1). Notably, expressional signals of
MUC1 and EMA in malignant were significantly higher
than benign (p = 0.001 and p = 0.011, respectively) (Fig. 2abased reverse phase protein array and western blotting. Relative
ed by samples. Relative expressional signals are displayed as a ratio
are significantly higher than benign cases (p = 0.001 and p = 0.011,
lot. GAPDH is included as an internal loading control. (f) The bar
ant; PM, probable malignant; B, benign; N, negative cytology; P,
Fig. 3 Hierarchical clustering and multidimensional scaling analysis. Each row represents a sample, and each column represents a protein. A
pseudo-colored representation of the ratio (log2-transformed and z-scored across the samples) is shown. On the bottom are the symbols of 6
proteins. On the right are the effusion fluid cytology (negative or positive), cancer diagnosis (negative or positive), and the category of three main clusters
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confirmed by western blotting (Fig. 2e and f). The high
expressions of both proteins were prominent in cells from
both ascites and pleural effusions. HSP90 and CA125
failed to demonstrate differences based on diagnosis.
Hierarchical clustering and correlations between biomarkers
To find the clustering of samples according to markers, a
total of 114 cases were analysed by hierarchical clustering
with the level of each marker. As shown in Fig. 3, three
main groups could be categorized with four samples not
included in any category. Category 1 consists exclusively of
negative cytology and category 2 exclusively of positive
cytology. Category 3 represents intermediate of category 1
and 2. The majority of cases of category 2 have higher ex-
pression of MUC1, EMA, Pan-CK, and CA125 that in the
other group. In contrast, category 1 represent the lowest
average activity in three (MUC1, EMA, and Pan-CK)
of the six markers assayed. In addition, the etiology of
effusion was different according to categories classified
(Table 2). Colon cancer was classified predominantly as
category 1 (60.0%), whereas ovarian cancer was categorizedTable 2 Association between clinicopathological characteristics
and three groups defined with cluster analysis
Categorya P value
1 No. (%) 2 No. (%) 3 No. (%)
Group 42 25 43
Malignant 0 (0.0) 25 (59.5) 17 (40.5) <0.001
Probable malignantb 19 (59.4) 0 (0.0) 13 (40.6)
Benign 23 (63.9) 0 (0.0) 13 (36.1)
Fluid
Ascites 19 (50.0) 8 (21.1) 11 (28.9) 0.155
Pleural effusion 23 (31.9) 17 (23.6) 32 (44.4)
Cytology result
Positive 0 (0.0) 25 (59.5) 17 (40.5) <0.001
Negative 42 (61.8) 0 (0.0) 26 (38.2)
Etiology (cancer)
Breast 2 (33.3) 2 (33.3) 2 (33.3) <0.001
Colon 9 (60.0) 1 (6.7) 5 (33.3)
Lung 4 (15.4) 11 (42.3) 11 (42.3)
Ovary 0 (0.0) 9 (60.0) 6 (40.0)
Others 4 (30.8) 2 (15.4) 7 (53.8)
Etiology
Heart failure 5 (55.6) 0 (0.0) 4 (44.4) 0.002
Liver cirrhosis 13 (81.3) 0 (0.0) 3 (18.8)
Inflammatory 5 (50.0) 0 (0.0) 5 (50.0)
aThe remaining 4 cases were not categorized into any grouping
bNo malignant effusion but history of malignancypredominantly as category 2 (64.3%). Of the benign eti-
ology, liver cirrhosis was classified predominantly to cat-
egory 1 (81.3%), while heart insufficiency and inflammatory
disease were equally categorized to 1 and 3, respectively.
Operating characteristics of tumor markers predicting
malignancy
Lastly, receiver operating characteristic (ROC) curves
were plotted to see the diagnostic accuracy of each marker
for the diagnosis of malignancy (Fig. 4). The areas under
curve (AUC) did not reveal a single marker as significantly
superior. Of the markers, HSP90 showed the best AUC
of 0.746 (95% CI, 0.503 – 0.741) and followed by EMA
of 0.728 (95% CI, 0.630 – 0.826) and MUC1 of 0.701(95%
CI, 0.600 – 0.803). Interestingly, CA125 showed no diag-
nostic value in this methodology. The cut-off values of the
five tumor markers (MUC1, EMA, Pan-CK, HSP90 and
TGF- β) were determined that best differentiated benign
from malignant effusions with the utmost specificity
(Fig. 4d). The sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV), and ac-
curacy for selected cut-off points for each tumor marker
are shown in Table 3. The sensitivity and specificity of
cytology for the diagnosis of malignancy was 57.3%
and 92.3%, respectively. Notably, the diagnostic value of
combined MUC1 and EMA was the same with cytology
examination (Table 3). Furthermore, the sensitivity, NPV,
and accuracy of the combined panel of five markers were
better than cytology by 14.7%, 7.5%, and 6.1%, respectively.
Discussion
Effusions in pleura or abdomen can hamper body func-
tions in a very severe way resulting in e.g. respiratory
failure, heart failure or fluid balance. Diagnostic evalu-
ation of effusions to determine and fight the cause, next
to mechanical relief is of major interest in planning gen-
eral or symptomatic therapy.
In order to evaluate the diagnostic values of putative
effusion tumor markers within the protein content in
the fluid compartment, we measured MUC1, EMA, Pan-
CK, HSP90, TGF-β and CA125 by a well-based RPPA
methodology in pleural effusions and ascites. This meth-
odology is based on antibody binding and measures the
binding by extremely sensitive electroluminescence to
cover even very low protein concentrations. MUC1 and
EMA levels were significantly higher in patients with
malignant effusions than those in benign effusions. Ana-
lysis of the ROC curves showed that EMA presented
the best AUC of 0.728 followed by MUC1 of 0.701 for
the diagnosis of malignant effusions. Although single
markers were less sensitive than cytopathology (52.0 for
MUC1and 48.0 for EMA), combined markers showed
higher sensitivity and accuracy. In addition, adding the
panel of tumor markers to the cytological analysis
Fig. 4 Receiver operating characteristic (ROC) curves. The ROC curves were plotted depending on MUC1 (a), EMA (b), and other tumor markers
(HSP90, Pan-CK, TGF-β, and CA125) (c). Operating characteristics of six tumor markers for malignant effusion diagnosis (d). Relative expressional
signals were represented as a ratio after normalization with GAPDH
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7.5%, and 6.1%, respectively, compared to cytopathologi-
cal examination alone. To the best of our knowledge,
diagnostic utility of MUC1 and EMA measured by well-
based RPPA have not been previously determined in
pleural effusion or ascites.
Body fluid cytopathology has traditionally been the
analytical method of choice for the detection of tumor
cells, as reflected in the International Union Against
Cancer/American Joint Committee on Cancer tumor-
node metastasis system [27]. However, in approximately
40% of cases, the cytological analysis does not provide
a decisive answer as to whether the effusion is ofmalignant cause or not [1–3]. In addition, the sensitivity
is primarily dependent on the experience of the cytolo-
gist, the number of morphologically intact tumor cells,
and the amount of material submitted [28–31]. One re-
cent study has suggested that current clinical guidelines
recommending a submission of 50 ml of pleural fluid
may be suboptimal [30]. Immunocytochemistry (ICC)
may complement cytology, but its utility in differentiat-
ing between benign pleural disease and mesothelioma is
somewhat controversial [32]. Building “cell blocks” or
“cyto blocks” out of effusions by embedding the cell con-
tent in agarose gel and build paraffin blocks for subse-
quently proceed with IHC requires a good cell content
Table 3 Diagnostic accuracy of each analysed markers
Tumor markers Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Cytology 57.3 92.3 93.5 52.9 69.3
MUC1 52.0 92.3 92.9 50.0 65.8
EMA 48.0 92.3 92.3 48.0 63.2
Pan-CK 36.0 92.3 90.0 42.9 55.3
HSP90 14.7 92.3 78.6 36.0 41.2
TGF-β 4.0 92.3 50.0 33.3 34.2
MUC 1 + EMA 57.3 92.3 93.5 52.9 69.3
MUC 1 + EMA+ Pan-CK 64.0 89.7 92.3 56.5 72.8
MUC 1 + EMA+ Pan-CK + HSP90 70.7 82.1 88.3 59.3 74.6
MUC 1 + EMA+ Pan-CK + HSP90 + TGF-β 72.0 82.1 88.5 60.4 75.4
PPV, positive predictive value; NPV, negative predictive value
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ing diagnostic approaches to immunocytochemistry or
building cell blocks are time consuming. These limita-
tions of cytological diagnosis of effusions drive the con-
tinual search for novel diagnostic auxiliaries. Such a test
can potentially negate the need for otherwise ascertain-
ing invasive procedures and provide rapid definitive
diagnosis.
This RPPA is an antibody-based proteomic technology
which is suitable for profiling of signaling protein’s ex-
pression and modification in low abundance [34, 35].
It allows concomitantly monitoring of the expression
of particular protein in hundreds of samples in a quanti-
tative manner. In addition, the advantages of high
throughput, sensitivity and cost effectiveness of RPPA
have accelerated the incorporation of this technology in
basic, preclinical and clinical research areas [36]. Espe-
cially in the upcoming field of “liquid biopsy”, in which
solved contents in body fluids (e.g. proteins, DNA) are
in focus to be markers for diagnosis or prognosis [37].
Although remarkable advances in the RPPA platform
have extended into the proteomic research area, there
are still limitations to the full strength of this method-
ology, including sophisticated printer requirement and
complicated study design. In this context, we have estab-
lished a well-based RPPA platform with technical im-
provements. Basically, our well-based RPPA platform
does not require the use of a printer arrayer, nor does it
require scoring of a dilution curve [24, 25]. Furthermore,
one substantial advantage is its capacity to measure
multiple proteins and develop a normalized metric based
on the expression of a largely invariant protein. This
platform has been successfully implemented into the
Antibody Portal of NCI (http://antibodies.cancer.gov) as
an antibody validation tool for new mAbs [26]. As most
proteomic assays, this methodology is also mainly
dependent on the antibody quality.A large number of studies on the potential diagnostic
usefulness of effusion fluid tumor markers have been
published, which report either encouraging [38, 39] or
disappointing results [40–42]. These disagreements can
be attributed to different factors, including the hetero-
geneity of tumor types, or the use of different method-
ologies and cut-off values in assays, among others. In
this study, we used a well-based RPPA with GAPDH
protein signal as an internal control to measure possible
degradation of the protein content from each sample.
This methodology shows an advantage that can evaluate
tumor marker level without the risk of low reliability
and poor validity [24, 25].
In recent years, there have been many tumor markers
that were used in the differential diagnosis of effusions.
However, no tumor marker alone had the sufficient diag-
nostic accuracy in discriminating malignant from benign
effusions. In addition, the clinical value of their com-
bined use has been evaluated with enhanced prediction
of malignancy. On the other hand, the use of combina-
tions is always followed by a decrease in specificity. In
this study, the combination of five tumor markers had
the maximum sensitivity and accuracy with acceptable
specificity. Even without definite diagnosis, these com-
bined tumor markers may at least aid in selecting pa-
tients when carrying out a more invasive procedures.
In OMIM (online mendelian inheritance for men) data-
base for proteins by the National Center for Biotechnology
Information, three synonyms for one protein, MUC1 are
named: Peanut-Reactive Urinary Mucin, PUM; Tumor
Associated Epithelial Polymorphic Epithelial Mucin, PEM;
Epithelial Membrane Antigen, EMA. Two others can be
found in literature: CA 15–3 and Episialin [20]. Basically,
MUC1 and EMA antibodies target the same protein.
EMA was first described in 1981 as an antiserum that
was made using a cell extraction [43]. EMA was therefore
not made with the knowledge of using a certain binding
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antibodies (E29), which were produced using milk-fat-
globule-membranes as an antigen, established in 1985 and
frequently applied in research [44]. Unfortunately, the spe-
cific binding site of EMA is still unknown. On the other
hand, the MUC1 antibodies (MA695) are precisely described
to recognize a sialylated carbohydrate antigen on MUC1
mucin [45]. It is likely that both antibodies bind to different
epitopes. Due to different degradation statuses of MUC1
molecule or fragmented secretion in an effusion, different
expression levels of MUC1 and EMA are expected. In
addition, Langner et al. tested and compared MUC1
(MA695) and EMA (E29) antibodies using immunohisto-
chemistry, not by western and reverse-phase protein array
[46]. Antibody avidity mainly relies on the proteomic tech-
nology used. Thus, we chose to incorporate MUC1 and
EMA by well-based RPPA to the existing tumor panel.
Noting the various binding affinities of single target pro-
teins to multiple epitopes of one protein, it is beneficial to
use a panel of monoclonal antibodies of different clones
covering different epitopes for more sensitive analysis.
Conclusions
In conclusion, we demonstrated that effusion fluid tumor
markers (MUC1, EMA, Pan-CK, HSP90 and TGF-β) mea-
sured by well-based RPPA have a limited albeit not a neg-
ligible value in the workup of effusions. The combined
assay of five tumor markers is helpful in increasing the
sensitivity and accuracy in diagnosing malignant effusions.
Further large scale studies need to be performed to ensure
whether this panel of tumor marker can replace or be-
come an alternative to other markers in patients with
metastatic disease.
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